CMS (康哲藥業) has announced its latest financial report, which shows a year-on-year decrease of 21.7% in revenue to RMB 3,611.1 million, a 25.2% decrease in gross profit to RMB 2,696.5 million, and a 52.8% decrease in net profit to RMB 903.4 million. The company's stock transfer registration office is Hong Kong Central Securities Registration Co., Ltd. During the reporting period, the company's four innovative drugs were approved for listing and included in the national medical insurance catalog, and a mid-term dividend of RMB 0.1507 per share was declared, a 51.9% decrease compared to the previous year. The company continues to promote the commercialization process of innovative products and actively explore the Southeast Asian market, with the aim of further improving performance.

CMS (康哲藥業) has announced its latest financial report, which shows a year-on-year decrease of 21.7% in revenue to RMB 3,611.1 million, a 25.2% decrease in gross profit to RMB 2,696.5 million, and a 52.8% decrease in net profit to RMB 903.4 million. The company's stock transfer registration office is Hong Kong Central Securities Registration Co., Ltd. During the reporting period, the company's four innovative drugs were approved for listing and included in the national medical insurance catalog, and a mid-term dividend of RMB 0.1507 per share was declared, a 51.9% decrease compared to the previous year. The company continues to promote the commercialization process of innovative products and actively explore the Southeast Asian market, with the aim of further improving performance.